

TRANSMITTAL FORM

Application Serial Number	10/029,406
Filing Date	December 19, 2001
First Named Inventor	Dai
Group Art Unit	1651
Examiner Name	Not Yet Assigned
Attorney Docket No.	INL-053
Patent No.	Not applicable
Issue Date	Not applicable


ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553) <input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Brief (in triplicate)
<input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____]	<input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) <input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Status Inquiry <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8
<input type="checkbox"/> Petition for Extension of Time	<input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application	<input type="checkbox"/> Additional Enclosure(s) (please identify below)
<input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations (A40-A43, B14 and C140-C163)	<input type="checkbox"/> Small Entity Statement <input type="checkbox"/> CD(s) for large table or computer program	RECEIVED AUG 05 2002 TECH CENTER 1600/2900
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Amendment After Allowance	
<input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above	<input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate)	

CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110
Tel. No.: (617) 248-7000
Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,

Diana M. Steel
Attorney for Applicants
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110

Date: July 25, 2002
Reg. No. 43,153
Tel. No.: (617) 310-8168
Fax No.: (617) 248-7100



RECEIVED

AUG 05 2002

TECH CENTER 1600/2900

PATENT
Attorney Docket No. INL-053
(4643/95)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Dai et al.
SERIAL NO.: 10/029,406 GROUP NO.: 1651
FILING DATE: December 19, 2001 EXAMINER: Not yet assigned
TITLE: PROTEIN S FUNCTIONAL ASSAY

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:


- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Date: July 25, 2002
Reg. No. 43,153

Tel. No.: (617) 310-8168
Fax No.: (617) 248-7100

2457981



Diana M. Steel
Attorney for Applicant(s)
Testa, Hurwitz, & Thibault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110



FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: INL-053 APPLICANT(S): Dai et al. SERIAL NO.: 10/029,406 FILING DATE: 12/19/01 GROUP: 1651				
U.S. PATENT DOCUMENTS								
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	A40	4,622,389	11/11/86	Nagasawa <i>et al.</i>	530	331	5/9/85	
	A41	4,692,406	9/8/87	Becker <i>et al.</i>	435	13	8/20/84	
	A42	4,849,403	7/18/89	Stocker <i>et al.</i>	514	2	5/9/86	
	A43	5,506,112	4/9/96	Lang <i>et al.</i>	435	13	1/10/92	
FOREIGN PATENT DOCUMENTS								
EXAM. INIT.	DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRAC T ONLY	ENGLISH LANG (Y/N)
	B14	A 0 229 234	7/22/87	EP		10/16/86	English	No
OTHER ART, JOURNAL ARTICLES, ETC.								
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)							
	C140	Beck <i>et al.</i> (1988), "Protein C: ein Inhibitor der Blutgerinnung," <i>Diagnose & Labor</i> , 38:35-42 (Abstract in English).						
	C141	Bertina (1990), "Specificity of Protein C and Protein S Assays," <i>Res. Clin. Lab.</i> , 20:127-138.						
	C142	Bertina <i>et al.</i> (1985), "Determination of Plasma Protein S – The Protein Cofactor of Activated Protein C," <i>Thrombosis Haemostasis</i> , 268-272.						
	C143	"Correlation of the APC Ratio with Free Protein S Antigen and with Protein C Activity" Appendix 5, 3 pages (Publication date not known).						
	C144	Dade Behring Marburg GmbH (2000), "Pathromitin [®] ," 1 page (Partial English translation provided).						
	C145	Deutsche Norm, DIN 58 911 (1988), "Kalibrierung ven Gerinnungszeit-MeBverfahren," 3 pages (English translation provided).						
	C146	Deutsche Norm DIN 58 939 (1987), "Refererzplasma," 4 pages (English translation provided).						
	C147	Diagnostika Stago "STACLOT [®] PROTEIN C Additional Information," 1 page (Publication date unknown).						
	C148	Diagnostika Stago "STACLOT [®] PROTEIN S Additional Information," 1 page (Publication date unknown).						
EXAMINER					DATE CONSIDERED			

RECEIVED

AUG 05 2002

TECH CENTER 1600/2900



FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: INL-053 APPLICANT(S): Dai et al. SERIAL NO.: 10/029,406 FILING DATE: 12/19/01 GROUP: 1651
U.S. PATENT DOCUMENTS		
C149	Exner <i>et al.</i> (1978), "A Sensitive Test Demonstrating Lupus Anticoagulant and its Behavioural Patterns," <i>Br. Haematol.</i> , 40:143-151.	
C150	Faioni <i>et al.</i> (1991), "Low Levels of the Anticoagulant Activity of Protein C in Patients with Chronic Renal Insufficiency: an Inhibitor of Protein C is Present in Uremic Plasma," <i>Thrombosis and Haemostasis</i> , 66(4):420-425.	
C151	Hoffmann <i>et al.</i> (1978), "Comparison of Reagents for Determining the Activated Partial Thromboplastin Time," <i>Thromb. Haemost.</i> , 39:640-645.	
C152	Holmberg <i>et al.</i> (1981), "Assessment of Blood Coagulation and General Haemostasis," <i>Haemostasis and Thrombosis</i> (Bloom <i>et al.</i> Ed.), Churchill Livingstone, London, 768-774.	
C153	Hoogendoorn <i>et al.</i> (1991), " α_2 -Macroglobulin Binds and Inhibits Activated Protein C," <i>Blood</i> , 78(9):2283-2290.	
C154	Koepeke <i>et al.</i> (1986), "Partial Thromboplastin Time-Test Proposed Performance Guidelines," <i>Thrombosis and Haemostasis</i> , 55:143-144.	
C155	Lottenberg <i>et al.</i> (1981), "Assay of Coagulation Proteases Using Peptide Chromogenic and Fluorogenic Substrates," <i>Methods in Enzymology</i> (Colowick <i>et al.</i> Ed.), vol. 8, Proteolytic Enzymes Part C (Lorand Ed.), Academic Press, 341-361.	
C156	Malm <i>et al.</i> (1988), "Changes In the Plasma Levels of Vitamin K-dependent Proteins C and S of C4b-binding Protein During Pregnancy and Oral Contraception," <i>Br. Hemat.</i> , 68:437-443.	
C157	Marlar <i>et al.</i> (1982), "Mechanism of Action of Human Activated Protein C, a Thrombin-Dependent Anticoagulant Enzyme," <i>Blood</i> , 59(5):1067-1072.	
C158	Pollner <i>et al.</i> (1992), "The Activated Partial Thromboplastin Time (APTT)," ECAT Assay Procedures-A Manual of Laboratory Techniques (Jespersen <i>et al.</i> Ed.), Kluwer Academic Publishers, 35-40.	
C159	Preda <i>et al.</i> (1990), "A Prothrombin Time-Based Functional Assay of Protein S," <i>Thromb. Res.</i> , 60:19-32.	
C160	Spaethe (1984), "Hämostase-Physiologie, Pathophysiologie, Diagnostik," 90 (English translation provided).	
C161	Stocker <i>et al.</i> (1988), "Practical Application of the Protein C Activator Protac from Agkistrodon Contortrix Venom," <i>Folia Haematol.</i> , 115: 260-263.	
C162	Stocker <i>et al.</i> (1986), "Protein C Activators in Snake Venoms," <i>Behring Inst. Mitt.</i> , 37-47.	
C163	Walker. (1990), "Guidelines on The Investigation and Management of Thrombophilia," <i>J. Clin. Pathol.</i> , 43:703-709.	
EXAMINER		DATE CONSIDERED

2457897_1

RECEIVED

AUG 05 2002

TECH CENTER 1600/2900